Abstract #4024

In vitro NMR spectroscopy identifies metabolic changes resulting from addition of a novel anti-cancer agent (AZD2014) to standard treatment, guiding potential imaging approaches

Nada Al-Saffar¹, Jasmin Sidhu¹, Udai Banerji¹, Yuen-Li Chung¹, and Martin O. Leach¹

¹The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom

Previous reports showed that activation of the PI3K/mTOR pathway is associated with chemoresistance in ovarian cancer cells, and this can be reversed by combining chemotherapy with the mTORC1/2 inhibitor vistusertib (AZD2014). This combination is now being pursued clinically. In this study, we used NMR spectroscopy to establish biomarkers for this combination in A2780Cis human ovarian carcinoma cells. We report that this combination resulted in decreases in lactate, PC, GPC and tCho and was associated with inhibition of glycolysis- and choline-regulatory enzymes. This indicates that choline metabolites and lactate may provide potential non-invasive biomarkers of tumour response to this combination therapy.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.